Shanghai Henlius Biotech, Inc. Class H · HKEX:2696
Shanghai Henlius Biotech, Inc. Class H — H1 2022 Earnings Presentation
51 slides from Shanghai Henlius Biotech, Inc. Class H's earnings presentation, August 2022
Slide 1: Henlius 1H22 Results Investor Presentation
Henlius(2696.HK) 1H22 Results Investor Presentation August 2022 1 © 2022 Henlius.
Slide 2: Contents
1 1H22 Business Highlights 2 Core Business Updates 2.1 Commercial Operation CONTENTS 2.2 Innovative Biologics R&D Milestones (Clinical Phase) 2.3 Early-stage R&D Strategies (Pre-clinical Phase) 2.4 Biosimilar Milestones 2.5 Manufacturing Capacity Breakthroughs 3 Financial Review & Outlook 2 © 2022 H
Slide 3: 1H22 Business Highlights
1 1H22 Business Highlights 3 © 2022 Henlius.
Slide 4: 1H22: The Pivotal 6 Months of Henlius' Evolution from Biotech to Biopharma
1H22: The Pivotal 6 Months of Henlius’ Evolution from Biotech to Biopharma Sustained operations during Covid outbreaks and lockdowns Doubled production capacity, breaking through the bottleneck Received NMPA approval for the first innovative biological drug, Serplulimab Accelerated product sales gro
Slide 5: 1H22 Key Milestones
1H22 Key Milestones IND of HLX53 (anti-TIGIT Fc fusion protein) approved by Our Mission: NMPA Affordable Innovation, Reliable Quality Reached license agreement with Palleon for bifunctional sialidases Reached license agreement with Organon, with payments up to US$541M on two mAbs products Products L
Slide 6: 5 Products Launched: Revenue Tops 1.29 Billion RMB
5 Products Launched: Revenue Tops 1.29 Billion RMB First Chinese biosimilar China’s first self-developed mAbs approved in China and EU First Chinese adalimumab manufactured in The only bevacizumab biosimilar Our first self-developed innovative China and EU GMP-certificated production with Phase 3 cl
Slide 7: High-performing Leadership Team with A Global Vision
High-performing Leadership Team with A Global Vision Jason Zhu Wei Huang James Guo Jifeng Zhang Jean-Michel Gries Kurt Yu President Chief Operation Officer SVP Chief Technology Officer President of Hengenix Chief Commercial Officer SVP SVP Biotech VP Wenjie Zhang Chairman Executive Director and CEO
Slide 8: Enhance R&D and Commercialisation Capabilities, Evolving to Biopharma
Enhance R&D and Commercialisation Capabilities, Evolving to Biopharma While maximising the commercial value of biosimilars, we rely on our own R&D expertise, complemented by external collaborations and license-in, to accelerate our innovation. Synergise China and US R&D centres, Assure Henlius quali
Slide 9: Company Scale: Rapid Team Expansion
Company Scale: Rapid Team Expansion Company Size and Composition* R&D and Technical Manufacturing Commercial General and Administrative R&D and Technical 1012 3500 Manufacturing 878 2,933 Commercial 803 3000 240 General & Administrative 240 2500 803 1,972 2000 172 1,629 157 451 1500 310 878 803 1012
Slide 10: 2.1 Commercial Operation
2.1 Commercial Operation 10 © 2022 Henlius.
Slide 11: 1H22 Sales: Growth Driven by Core Products
1H22 Sales: Growth Driven by Core Products Revenue by Product(in million RMB) Ex-Factory Volume * (Unit: 1,000 Vials) HANLIKANG HANQUYOU HANDAYUAN HANSIZHUANG BD & Others HANLIKANG HANQUYOU HANDAYUAN HANSIZHUANG 1400 Total Vials 1,477.14 1,289 759.23 Total Vials 897.57 108 1200 77 606.08 578.03 20 1
Slide 12: HANQUYOU (trastuzumab): Rapid Increase in Production Volume
HANQUYOU (trastuzumab): Rapid Increase in Production Volume Optimised distribution network Better market access • 150mg: Entered national reimbursement drug list and completed • Optimised distributor & DTP pharmacy channels tenders on procurement platforms in all provinces and and municipalities. Ga
Slide 13: HANQUYOU (trastuzumab): Outstanding Sales Performance
HANQUYOU (trastuzumab): Outstanding Sales Performance Sales performance Efficient sales investment Total estimated accessed market rate reached 70%* as of Enhanced efficiency to achieve sustainable development Jun 30, 2022, market share in accessed market reached 50% and returns Market Share Market
Slide 14: HANQUYOU: 60mg Specification Launched
HANQUYOU: 60mg Specification Launched, Advanced Leading Position in the Trastuzumab Market Establishing new standard among peers Adjustable Dosage 01 Suitable for Asian Female Patients 02 Dual Drug Specifications Standardising Drug Adoption Superior Formulation 03 No preservatives, fewer side effect
Slide 15: HANSIZHUANG (serplulimab): Successful Launch in March
HANSIZHUANG (serplulimab): Successful Launch in March DTP channel optimisation Access and market penetration • Pursued synergistic effect with HANQUYOU, • Accelerated bidding established efficient distribution network Complied with national drug code system regulation, completed • Maximised access b
Slide 16: HANSIZHUANG: Under China NDA Review for sqNSCLC and SCLC Indications
HANSIZHUANG (serplulimab): Under China NDA Review for sqNSCLC and SCLC Indications Market prospects • 800k+ new lung cancer patients every year (170k+ in Exploring lung cancer sqNSCLC, 120k + in SCLC) • HANSIZHUANG would potentially be the world’s first PD-1 inhibitor treatment potential for the fir
Slide 17: HANLIKANG (rituximab): Market Leader amid Competition and COVID-19
HANLIKANG (rituximab) :Market Leader amid Competition and COVID-19 Pandemic Market Access Sales Performance* 100mg: Ex-factory Sales* (Unit:10,000 vials) Listed on the procurement platform in 30 provinces and 80.8 75.9 municipalities except Yun Nan by the end of June; Covered 57.8 51.8 by medical in
Slide 18: HANLIKANG: Rapidly Claiming Market Share in RA Treatment
HANLIKANG: Rapidly Claiming Market Share in RA Treatment Consolidated leadership in core Approved for RA Indication, proactively market and expanded further preparing NRDL negotiations By June, the number of Top 300+ hospitals with HANLIKANG prescriptions has climbed 22% since the beginning of the y
Slide 19: 2.2 Innovative Biological Drugs R&D Milestones (Clinical Phase)
Innovative Biological Drugs 2.2 R&D Milestones (Clinical Phase) 19 © 2022 Henlius.
Slide 20: Product Pipeline - Innovative Biological Drugs
Product Pipeline - Innovative Biological Drugs Products Targets Indications Pre-clinical IND Phase 1 Phase 2 Phase 3 NDA Launch Business Partners Launc HANSIZHUANG -hed PD-1 MSI-H solid tumours (serplulimab) (1) (serplulimab squamous non-small cell lung cancer 1L Global multi-centre clinical study i
Slide 21: Pipeline Catalysts in 2H22 and 2023
Pipeline Catalysts in 2H22 and 2023 2H2022 1H2023 2H2023 HLX10 – Non-squamous Non-Small Cell Lung HLX10 – Esophageal squamous cell carcinoma HLX10 – Extensive Stage Small Cell Lung Cancer (nsNSCLC) 1L (CN) (ESCC) 1L (CN) Cancer (ES-SCLC) 1L (EU) NDA/BLA/MAA HLX10 – Extensive Stage Small Cell Lung Ca
Slide 22: Serplulimab: Clinical Trials on Major Oncology Indications
Serplulimab: Clinical Trials on Major Oncology Indications Serplulimab approved for 10+ clinical trial projects in China, the US, the EU, etc. NDA Phase 3 Phase 1/2 sqNSCLC 1L ESCC 1L HCC 1L Serplulimab + Chemo Serplulimab + Chemo Serplulimab + HANBEITAI (bevacizumab) + HLX07 (EGFR) NMPA NDA under r
Slide 23: Serplulimab Global Layout: Registration Plan on BLA in the US and MAA in the EU
Serplulimab Global Layout: Clear Registration Plan on BLA in the US and MAA in the EU Visionary Global Layout • Actively filling the gap in 1L SCLC in the next 5 years. MSI-H Squamous Cell Esophageal Lung Cancer Gastric Hepatocellular • Based on the positive feedback received from FDA on March 2, So
Slide 24: Serplulimab: Presented Orally at ASCO, Clinical Data for 1L ES-SCLC
Serplulimab: Presented Orally at ASCO, Shows Extraordinary Clinical Data for 1L ES-SCLC ASCO data cut-off: 2021-10-22 Serplulimab+chemo Placebo+chemo (n=389) (n=196) Events, n (%) 146(37.5) 100(51.0) Median 15.4 mo (13.3,NE) 10.9 mo OS(95% CI) (10.0,14.3) Stratified HR (95% CI) = 0.63 (0.49,0.82) p<
Slide 25: Serplulimab: Better mOS and HR Results
Serplulimab: Better mOS and HR Results data cut-off: 2021-10-22 Phase 3 Trial Name IMpower133 CASPIAN KEYNOTE 604 ASTRUM-005 Company Roche AstraZeneca Merck & Co Henlius Investigational drug Atezolizumab Durvalumab Pembrolizumab Serplulimab Randomized Double Blind 2- Randomized Double Blind 2-arm Op
Slide 26: Advancement of Clinical Pipeline (Ph 2/Ph 3)
Advancement of Clinical Pipeline (Ph 2/Ph 3) • A recombinant humanised anti-EGFR monoclonal • Has strong oral bioavailability and safety profile. antibody, with a LONGER half-life compared with Expected to be the world’s first BRAF inhibitor HLX07 HLX208 approved in adult LCH indication treatment Ce
Slide 27: HLX22: Great Efficacy in Ph 2 Clinical Trial
HLX22: Great Efficacy in Ph 2 Clinical Trial A candidate of 1L HER2+ gastric cancer treatment with great potential 1. HLX22 emerges as a strong candidate with an expected ORR of 85% in HER2+ locally advanced/metastatic GC, based on the efficacy data from a double-blind, randomized, multi-centre Ph 2
Slide 28: HLX07 (EGFR Inhibitor): Ongoing Clinical Trials
HLX07 (EGFR Inhibitor): Ongoing Clinical Trials Indications Strategic Significance Stage • HLX07-FIH Solid tumour (ST) • Phase 1 dose escalation, 19 patients enrolled, no DLTs, ORR 5.3%, mPFS 1.87m. • Ph 1 • HLX07-002 Solid tumour (ST) • HLX07-002 56 patients enrolled, no DLTs, ORR 16.1%. • Ph 1b/2
Slide 29: HLX208 (BRAF V600E Inhibitor): Ongoing Clinical Trials
HLX208 (BRAF V600E Inhibitor): Ongoing Clinical Trials Indications Strategic Significance Stage • Phase 1 dose escalation with primary efficacy achieved • Solid tumour - NeuPharma • 26 subjects evaluable, 20 cases achieved SD, DCR Ph 1 77%, 13 (50%) cases see SOD decrease • Fast to Market Scheme • N
Slide 30: HLX04-O: Ph 1/2 Showed Safety and Preliminary Efficacy
HLX04-O: Ph 1/2 Showed Safety and Preliminary Efficacy Clinical Trials Ph 1 Ph 2 Ph 3 HLX04-O-wAMD-CN01 Ph 1/2, n=20, HLX04-O, primary endpoint: Mean change of BCVA at 12W. HLX04-O-wAMD-CN Ph 3,n=388, HLX04-O/Lucentis, primary endpoint: Mean change of BCVA at 48W. HLX04-O-wAMD-Global Ph 3,n=388 HLX0
Slide 31: Highlights of Early-Stage Clinical Assets (Ph 1/2)
Highlights of Early-Stage Clinical Assets (Ph 1/2) • With differentiated mechanism, no hook • Strong immune regulating effects in TME effect compared to previous CD73 inhibitors HLX23 HLX53 • HLX53 combo with Serplulimab was • More significantly and persistently inhibit (CD73) CD73 activity and indu
Slide 32: 2.3 Early Stage R&D Strategies (Pre-clinical Phase)
Early Stage R&D Strategies 2.3 (Pre-clinical Phase) 32 © 2022 Henlius.
Slide 33: R&D Goal: Antibody-centric approach with further innovation
R&D Goal: Antibody-centric approach with further innovation to be the backbone of innovative drug ecosystem 2025-2030 2020-2025 5 2010-2020 5 Benchmark in Years Backbone of innovative drug ecosystem 10 Years innovative biologics Years Leader in biosimilars Further Innovation with data-driven Focus o
Slide 34: R&D Strategy: Build up AXC Platform, Empower Further Innovation
R&D Strategy: Build up AXC Platform, Empower Further Innovation Within 1 Year 1-3 Years Small molecule Cell (ACC) (ADC) Enzyme Radionuclide (AEC) (ARC) PROTAC Oligonucleotide (APC) (AOC) • Antibody-centric, Evolved Modality (AXC: Antibody X-molecule conjugate) • Expand R&D of XXC products, focusing
Slide 35: Pre-Clinical Pipeline: Aim to Solve Unmet Medical Needs
Pre-Clinical Pipeline: Aim to Solve Unmet Medical Needs • Induces OX40 clustering through tetravalent binding and exerts immune activation • Potential first-in-class monoclonal antibody • Exhibits dose-dependent tumour-killing effect in multiple • Clear MOA, unique immune microenvironment modulation
Slide 36: 2.4 Biosimilar Milestones
2.4 Biosimilar Milestones 36 © 2022 Henlius.
Slide 37: Product Pipeline - Biosimilars
Product Pipeline - Biosimilars Products Targets Indications Pre-IND IND Phase 1 Phase 2 Phase 3 NDA Launch Business Partners non-Hodgkin lymphoma, HANLIKANG CD20 chronic lymphocytic leukemia and (rituximab)(1) Abbott rheumatoid arthritis(2) HANQUYOU breast cancer, HER2 The first Chinese mAb biosimil
Slide 38: Globalisation: Out-Licensing in 100+ Countries / Regions
Globalisation: Out-Licensing in 100+ Countries / Regions Out-licensed products: 1H22 Biosimilars license-out overseas: • 7 biosimilars: HANLIKANG, HANQUYOU, HANDAYUAN, HANBEITAI, HLX05, HLX11, HLX14 Organon US$541M (upfront US$73M) • 3 innovative biological drugs: HANSIZHUANG, HLX04-O, HLX35 (EGFRx4
Slide 39: Blockbuster Out-licensing Deal: Organon
Blockbuster Out-licensing Deal ORGANON HLX11 (Pertuzumab) HLX14 (Denosumab) (NYSE: OGN) Ph 3 neoadjuvant treatment for breast Ph 3 postmenopausal women with cancer (BC) osteoporosis (OP) MERCK spinoff in June 2021 ⚫ Up to a total of US$541M in potential revenue ⚫ Upfront payment of US$73M (70+3) Glo
Slide 40: A Leading Global Technology Platform for Biologics
A Leading Global Technology Platform for Biologics: Flexible and Efficient to FIH and Commercialisation • High throughout developability: selection of robust molecules • Upstream ➢ Stable cell line with high titer ➢ Proprietary cell culture media development ➢ Intensified process State-of-art analyt
Slide 41: 2.5 Manufacturing Capacity Breakthroughs
2.5 Manufacturing Capacity Breakthroughs (Strengthen Market Leading Position in Manufacturing Technology & Quality) 41 © 2022 Henlius.
Slide 42: Songjiang First Plant: 24,000L Additional Capacity Approved for HANQUYOU
Songjiang First Plant: 24,000L Additional Capacity Approved for HANQUYOU Leading commercial manufacturing capacity • Total manufacturing capability (SJ1&Xuhui): 48,000L • Commercial GMP batches: 450+(2019~) • Manufacturing success rate: ≥98% • Manufacturing and quality related employees: 878 • Produ
Slide 43: Production Capacity to Reach 144,000L by 2026
Production Capacity to Reach 144,000L by 2026 Technology upgrade and innovation ➢ Established new technology platform ➢ Expanded the cost advantages of commercial production with 15,000L stainless steel bioreactor system ➢ Optimised process to increase efficiency Production capacity & business impro
Slide 44: Financial Review & Outlook
3 Financial Review & Outlook 44 © 2022 Henlius.
Slide 45: Financial Highlights
Financial Highlights • Rapid growth of total revenue: mainly resulted from the increase of 1H22 1H21 Growth In million RMB In million RMB YOY sales volumes of our core products HANLIKANG (rituximab) and HANQUYOU (trastuzumab), and the launch of HANSIZHUANG Revenue 1,289.4 633.6 103.5% (serplulimab),
Slide 46: 1H22 R&D: Invest in Innovative Drugs and Improve Efficiency
1H22 R&D: Invest in Innovative Drugs and Improve Efficiency R&D Expenditure (in million RMB) Ratio of Innovative Biological Drugs Expenses Capitalised Expensed 90% 2,000 1,800 1,711 1,764 85% 82% 1,600 80% 75% 1,400 75% 894 1,024 70% 1,200 65% 1,000 65% 827 800 757 739 60% 600 55% 393 534 452 400 81
Slide 47: 1H22 Profitability: Net Loss Ratio & Expense Ratio Decreased
1H22 Profitability: Net Loss Ratio & Expense Ratio Decreased The Ratio of Loss to Total Revenue Narrowed Down The Ratios of Expense to Total Revenue Decreased Profit Net Margin Loss Ratio 1H 2022 1H 2021 0% 80% -20% 71% -50% 70% -62% -100% 60% -150% 50% 41% -200% 40% 35% 31% -250% 29% 30% 24% -300%
Slide 48: 2H22 Top Priorities for Henlius
2H22 Top Priorities for Henlius Registration, Manufacturing, Quality Commercialisation R&D and BD and Technical Speed up SJ2 Construction; HANQUYOU becomes a market leader ➢ Well prepared for FDA BLA submissions of HLX02 and HLX10 in 2023 Optimise the efficiency of Xuhui&SJ1 HANSIZHUANG exceeds the
Slide 49: 2H22 Outlook
2H22 Outlook Rapidly Evolving from Biotech to Biopharma… 2H22 Performance Guidance 49 © 2022 Henlius.
Slide 50: Disclaimer
声明 Disclaimer • 复宏汉霖、陈述人或提供人对本文件内容(文件内容亦有可能包括前瞻性陈述)均不做出明示或默示的保证、声明或陈述(包括但不限于:本内容针对为任意特定目的而关于内容 所具有的及时性、通用性、精确性的声明,或者关于使用本文件内容所获得信息无误可信的声明)。如因有关内容存在错误、遗漏或失准之处而引致的行为或结果,复宏汉霖、陈 述人或提供人对此不承担责任。 • 本文件及其中所包含内容的所有权利包括版权均由复宏汉霖独家所有,其中相关的“Henlius” 和“复宏汉霖”字样、图案及相关LOGO标识均为复宏汉霖合法所有的字号、商标 和标识。未经复宏汉霖书面同意,任何第三方不得以包括
Slide 51: © 2022 Henlius.
@ Henlius Reliable Quality Affordable Innovation
Shanghai Henlius Biotech — H1 2022 Earnings Presentation on 6ix